罗格列酮对胰岛素抵抗高血压大鼠主动脉功能的影响

为探讨罗格列酮(rosiglitazone,ROSI)对胰岛素抵抗高血压大鼠(insulin resistant-hypertensive rats,IRHR)主动脉功能的影响及其可能机制,用高果糖饲养Sprague-Dawley大鼠8周,制备IRHR模型,并通过相关指标的检测判断造模是否成功。随后采用血管环灌流方法,观察各实验组动物离体胸主动脉环对新福林(L-phenylephrine,PE)、氯化钾(KCl)的收缩反应和对乙酰胆碱(acetylcholine,ACh)、硝普钠(sodium nitroprusside,SNP)的舒张反应：以及用一氧化氮合酶(nitric oxide synthase,NOS)的抑制剂N-硝基-L-精氨酸甲酯(N^ω-nitro-L-arginine methyl ester,L-NAME)预孵育血管30min后,主动脉环对ACh的舒张反应：同时对各实验组血清一氧化氮(nitric oxide,NO)的含量进行测定。结果显示：(1)罗格列酮能降低IRHR的收缩压、血清胰岛素水平,改善胰岛素抵抗。(2)高果糖组动物主动脉对PE、KCl的收缩反应明显增强,对ACh的舒张反应明显减弱,ROSI可逆转上述作用。(3)用L-NAME预处理后,高果糖组动物主动脉对ACh的舒张反应进一步减弱,ROSI可部分对抗上述作用。(4)各组大鼠离体主动脉对SNP的舒张反应无显著性差异。(5)ROSI对对照组大鼠主动脉功能的影响不明显。(6)与对照组相比,高果糖组动物血清NO含量显著降低,用ROSI处理后,血清NO含量显著增加。上述结果表明,ROSI能改善IRHR主动脉的舒张功能,其作用的机制可能是部分通过NOS途径促进内皮NO释放,或是通过降低血压、血清胰岛素水平,以及改善胰岛素抵抗等作用,导致血管舒张。

Effects of rosiglitazone on aortic function in rats with insulin resistant-hypertension

Rosiglitazone (ROSI), thiazolidione peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activator, reduces insulin resistance in patients with type 2 diabetes (T2DM). It also improves vascular reactivity in T2DM patients and some animal models by unclear mechanisms. In order to investigate the effect of ROSI on aortic systolic and diastolic function of insulin resistant-hypertensive rats (IRHR) and the underlying mechanism, male Sprague-Dawley (SD) rats were fed with high fructose (HF) for 8 weeks to induce IRHR model. To verify IRHR model, systolic blood pressure (SBP), fasting blood sugar (FBS), fasting serum insulin (FSI) were measured respectively in each group, and insulin sensitive index (ISI) was also calculated. Subsequently, the vascular function test was performed. The thoracic aortic ring of SD rats was mounted on a bath system. The effect of rosiglitazone on the contraction elicited by L-phenylephrine (PE) and potassium chloride (KCl) and the relaxation induced by acetylcholine (ACh) and sodium nitroprusside (SNP) were measured. To explore the mechanism, nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) was used and serum nitric oxide (NO) was measured . The results obtained were as follows: (1) Rosiglitazone reduced the level of SBP, serum insulin and improved insulin resistance in IRHRs. (2) The contractive responses of thoracic aortic rings to PE and KCl were enhanced and the relaxation response to ACh was depressed significantly in the HF group, and the effect was reversed by ROSI. (3) After pretreatment with L-NAME, the relaxation response to ACh was further impaired in the HF group, this effect was partly reversed by ROSI. (4) Sodium nitroprusside (SNP)-induced vasodilator responses did not differ significantly among the groups. (5) Aortic systolic and diastolic function of the control group was not affected markedly by ROSI. (6) Compared with the control group, serum nitric oxide was significantly reduced in the HF group, but after rosiglitazone treatment it was remarkably increased. These findings suggest that ROSI can improve aortic diastolic function of insulin resistant-hypertensive rats, the mechanism of this effect might be associated with an increase in nitric oxide mediated partly by NOS pathway, a decrease in the level of blood pressure, serum insulin and the improvement of insulin resistance.